Table 3.
LV contractility in following β-adrenergic stimulation
| Baseline | 5 μg·kg−1·min−1 Dobutamine | Contractile Reserve, %increase | |
|---|---|---|---|
| HR, beats/min | |||
| Con | 92 ± 4 | 138 ± 6 | 50 |
| HF | 112 ± 5 | 151 ± 7 | 35 |
| HF-TR | 98 ± 8 | 135 ± 4 | 38 |
| ESPVR, mmHg/ml | |||
| Con | 7 ± 3 | 22 ± 3 | 210 |
| HF | 12 ± 3 | 20 ± 4 | 65 |
| HF-TR | 11 ± 4 | 31 ± 6 | 176 |
| PRSW, mmHg | |||
| Con | 48 ± 7 | 99 ± 7 | 107 |
| HF | 71 ± 10 | 129 ± 7* | 82 |
| HF-TR† | 74 ± 7 | 155 ± 13* | 109 |
Values are means ± SE. HR, heart rate; ESPVR, end-systolic pressure-volume relationship; PRSW, preload recruitable stroke work.
*
Significance is indicated at P < 0.05 vs. Con, same dose value.
†
P < 0.05 vs. Con (repeated-measures ANOVA; group main effect).